. Flow cytometric analysis of RAET1g surface expression in wild-type and b3-null endothelial cells. RAET1g was not detectable on the surface of mouse endothelial cells. Mouse IgG1 was used as negative control, and antibody against b3-integrin was used to confirm b3-integrin deficiency in b3-null endothelial cells. 
. Flow cytometric analysis of FLK1 and b3-integrin in Rpl29-wild-type, Rpl29-heterozygous and Rpl29-null primary endothelial cells. Mouse IgG1 was used as negative control. No changes in surface expression of either (A) FLK1 or (B) b3 integrin were observed in Rpl29-heterozygous or Rpl29-null endothelial cells when compared with wildtype controls.
Fig. S4. VEGF-stimulated ERK-phosphorylation.
Western blot analysis of pERK1/2 levels to total ERK1/2 in endothelial cells treated with SCM and Rpl29-siRNA show that pERK1/2 protein levels were not decreased following Rpl29 knockdown with siRNA in comparison to SCM-siRNA when cells were exposed to VEGF. Bar charts represent densitometry readings of RPL29 levels were compared to loading control HSC70 and pERK1/2 protein levels relative to total ERK1/2. 6 cells) were injected subcutaneously into the flank of 8-week-old WT and Rpl29-heterozygous mice and tumours were allowed to grow for 14 days. Size-matched tumours were ressected and tumours allowed to metastasise to the lungs. The mice were then killed 6 weeks later at which point they showed no adverse effects. Lungs were removed from the mice and examined for surface metastases. No significant difference in lung metastasis was observed between wild-type and Rpl29-null mice. Metastasis was measured by counting LLC metastasis on the surface of lungs/mouse (n=4-5, mean ± s.e.m.). 
Fig. S10. Cell migration assay.
Six-well plates were coated with a mixture of PureCol (Nutacon), human plasma fibronectin (Millipore), and 0.1% gelatine and seeded with 300,000 endotheilal cells per well. Cells were allowed to proliferate until confluent, washed with Opti-MEM and incubated for 2 hours in Opti-MEM 2.5% FCS. Cells in each well were scratched in a straight line with a P200 tip, and media was exchanged with a fresh Opti-MEM 2.5% FCS media with or without 30 ng/ml VEGFA. An inverted time-lapse microscope was used to follow wound healing due to cell migration for up to 24 hours, and data was analysed using ImageJ. No significant difference was observed in serum-stimulated endothelial cell migration between 8 and 24 hours between samples treated with Rpl29 and SCM siRNA. Values are given as representations of wound closure in pixels.
Fig. S11. Protein synthesis assay.
Ten thousand cells were plated in each well of a 96-well plate pre-coated with PureCol (Nutacon), human plasma fibronectin (Millipore) and 0.1% gelatine. Protein synthesis was measured using Click-iT AHA Alexa Fluor 488 Protein Synthesis HCS Assay (Invitrogen) following the manufacturers protocol with methionine-free RPMI (Invitrogen). No significant difference was observed in protein synthesis between samples treated with Rpl29 and SCM siRNA. Puromycin (1mM) was used as a positive control for protein synthesis inhibition. (n=3; nsd, not significant; **P<0.01). Table S1 . List of genes whose expression was upregulated in b3-null endothelial cells compared with wild-type (P<0.01). 
